EUVIMEDEUVIMED entdecken
Open Access

An in silico analysis of effective siRNAs against COVID‐19 by targeting the leader sequence of SARS‐CoV‐2

Anand Kumar Pandey iD, Shalja Verma

ADVANCES IN CELL AND GENE THERAPY · 2021

DOI: 10.1002/acg2.107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ADVANCES IN CELL AND GENE THERAPY, 2021. Verfasst von Anand Kumar Pandey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology Engineering Institute of Engineering and Technology Bundelkhand University Jhansi India. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

RNAi therapySARS‐CoV‐2leader sequenceoff‐target effectsiRNA

Autor:innen und Institutionen

  • Department of Biotechnology Engineering Institute of Engineering and Technology Bundelkhand University Jhansi India.
  • Department of Biochemical Engineering and Biotechnology Indian Institute of Technology New Delhi India.
  • NIMR-ICMR New Delhi India.

ORCID-Profile: Anand Kumar Pandey

Zitieren

APA

Pandey, A. K., & Verma, S. (2021). An in silico analysis of effective siRNAs against COVID‐19 by targeting the leader sequence of SARS‐CoV‐2. ADVANCES IN CELL AND GENE THERAPY. https://doi.org/10.1002/acg2.107

Vancouver

Pandey AK, Verma S. An in silico analysis of effective siRNAs against COVID‐19 by targeting the leader sequence of SARS‐CoV‐2. ADVANCES IN CELL AND GENE THERAPY. 2021. doi:10.1002/acg2.107

BibTeX
@article{Pandey2021,
  author = {Pandey, Anand Kumar and Verma, Shalja},
  title = {An in silico analysis of effective siRNAs against COVID‐19 by targeting the leader sequence of SARS‐CoV‐2},
  journal = {ADVANCES IN CELL AND GENE THERAPY},
  year = {2021},
  doi = {10.1002/acg2.107}
}
Kostenlos starten →